Jacobson Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Derek Sum
Chief executive officer
HK$18.0m
Total compensation
| CEO salary percentage | 32.91% |
| CEO tenure | 9.7yrs |
| CEO ownership | 70.3% |
| Management average tenure | no data |
| Board average tenure | 9.5yrs |
Recent management updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Jacobson Pharma Corporation Limited's (HKG:2633) CEO For Now
Jul 21
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Jacobson Pharma Corporation Limited's (HKG:2633) CEO For Now
Jul 21Jacobson Pharma Corporation Limited (HKG:2633) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
Jul 02Here's Why We Think Jacobson Pharma (HKG:2633) Might Deserve Your Attention Today
Jun 13Jacobson Pharma Corporation Limited's (HKG:2633) 28% Price Boost Is Out Of Tune With Earnings
Jan 06There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump
Nov 22Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | HK$18m | HK$6m | HK$301m |
| Dec 31 2024 | n/a | n/a | HK$277m |
| Sep 30 2024 | n/a | n/a | HK$253m |
| Jun 30 2024 | n/a | n/a | HK$220m |
| Mar 31 2024 | HK$21m | HK$4m | HK$186m |
| Dec 31 2023 | n/a | n/a | HK$221m |
| Sep 30 2023 | n/a | n/a | HK$141m |
| Jun 30 2023 | n/a | n/a | HK$158m |
| Mar 31 2023 | HK$14m | HK$3m | HK$175m |
| Dec 31 2022 | n/a | n/a | HK$207m |
| Sep 30 2022 | n/a | n/a | HK$203m |
| Jun 30 2022 | n/a | n/a | HK$190m |
| Mar 31 2022 | HK$5m | HK$3m | HK$178m |
| Dec 31 2021 | n/a | n/a | HK$166m |
| Sep 30 2021 | n/a | n/a | HK$154m |
| Jun 30 2021 | n/a | n/a | HK$164m |
| Mar 31 2021 | HK$5m | HK$4m | HK$174m |
| Dec 31 2020 | n/a | n/a | HK$183m |
| Sep 30 2020 | n/a | n/a | HK$191m |
| Jun 30 2020 | n/a | n/a | HK$203m |
| Mar 31 2020 | HK$5m | HK$4m | HK$214m |
| Sep 30 2019 | n/a | n/a | HK$273m |
| Jun 30 2019 | n/a | n/a | HK$259m |
| Mar 31 2019 | HK$5m | HK$4m | HK$245m |
Compensation vs Market: Derek's total compensation ($USD2.31M) is above average for companies of similar size in the Hong Kong market ($USD402.65K).
Compensation vs Earnings: Derek's compensation has been consistent with company performance over the past year.
CEO
Derek Sum (62 yo)
Mr. Kwong Yip Sum, also known as Derek, is Executive Chairman of the Board of JBM (Healthcare) Limited from June 12, 2025. Mr. Sum was Non-Executive Chairman of the Board of JBM (Healthcare) Limited from S...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 9.7yrs | HK$17.99m | 70.28% HK$ 2.0b | |
| VP of Administration & Executive Director | 8.7yrs | HK$3.15m | 0.50% HK$ 14.5m | |
| Executive Director | 9.5yrs | HK$7.57m | 2.28% HK$ 65.9m | |
| Independent Non-Executive Director | 9.2yrs | HK$230.00k | no data | |
| Member of Scientific Advisory Committee | 9.5yrs | no data | no data | |
| Member of Scientific Advisory Committee | 9.5yrs | no data | no data | |
| Member of Scientific Advisory Committee | 9.5yrs | no data | no data | |
| Independent Non-Executive Director | 9.2yrs | HK$230.00k | 0.030% HK$ 870.1k | |
| Independent Non-executive Director | less than a year | no data | no data |
Experienced Board: 2633's board of directors are considered experienced (9.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 05:48 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jacobson Pharma Corporation Limited is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Cho Ming Lau | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Fangfang Li | Cinda International Research Limited |